OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).

On December 11, 2025, OKYO Pharma Limited announced new analyses from a Phase 2 clinical trial of urcosimod, showing positive results in treating neuropathic corneal pain (NCP). The trial demonstrated that patients treated with 0.05% urcosimod experienced not only a reduction in pain but also favorable changes in corneal nerve structure, unlike the placebo group. These findings suggest urcosimod’s potential as a first-in-class therapeutic approach for NCP, highlighting its promise in restoring corneal nerve health and supporting further development.

The most recent analyst rating on (OKYO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and other ocular diseases. The company is listed on the NASDAQ Capital Market and is committed to discovering and developing novel molecules to address severe ocular conditions.

Average Trading Volume: 141,826

Technical Sentiment Signal: Hold

Current Market Cap: $74.09M

For an in-depth examination of OKYO stock, go to TipRanks’ Overview page.